# Self Titration With Apidra to Reach Target Study (START)

> **NCT01013571** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 493 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin glargine
- **DRUG:** Apidra (insulin glulisine)

## Key facts

- **NCT ID:** NCT01013571
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2012-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01013571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01013571, "Self Titration With Apidra to Reach Target Study (START)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01013571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*